Introducing the team
The drive to adapt a lab discovery into treatment of neurodegeneration
Teitur Trophics is breaking new ground when it comes to neurodegenerative diseases. After identifying a previously unknown means of preserving functioning brain cells, the biotech company’s founders aim to translate that discovery into therapies for conditions with almost no current treatment options. According to Co-Founder and CEO Simon Mølgaard, …
From toxin to remedy, and operating room to the boardroom
Even though it’s based on venom from one of the deadliest snakes in the world, the lead product of biotech startup VarmX can be life-saving for patients on blood thinners. It’s an unexpected turn, but those are the norm for the Dutch company’s Chairman and CEO, Dr. Jan Öhrström. His CV runs the gamut from […]
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
We are proud to support/co-lead @Teitur Trophics €28M Series A financing.
Building a legacy based on deep-rooted integrity
For Mukhopadhyay, the cornerstone of a future-proofed firm with a global reach is a leadership philosophy that embodies decency and humility.